Blood cardiometabolic impairments are associated to high blood pressure which is a pivot cardiovascular risk factor. The objective of this study was to assess cardiometabolic risk factors rates in subjects with high blood pressure in the steady state. A total of 292subjects, 107 cases and 185 controls were enrolled in cross-sectional study. Clinical and biological data were assessed during visits and after overnight fasting. Data were analyzed on R. A p-value < 0.05 was considered for statistical significance.Univariate analysis showed thatage > 50 years, visceral obesity, metabolic syndrome and hs- CRP ≥ 3 mg/L were significant predictors of high blood pressure: OR = 2.1, 95% CI [1.3-3.5], p = 0.003; OR = 1.6, 95% CI [1.0-2.6], p = 0.05;  OR = 3.3; 95% CI [2.0-5.4], p < 0.001;  OR = 16.8; 95% CI [9.4-31.4], p < 0.001, respectively. Multivariate analysis showed a positive association between obesity, metabolic syndrome, hs-CRP and high blood pressure: aOR = 2.29; 95% CI [1.14-4.69], p = 0.02; aOR = 3.47; 95% CI [1.64-7.61], p = 0.001; aOR = 18.10; CI, 2.5% to 95% [9.40-36.99], p < 0.001, respectively. In contrast, female sex was negatively associated with high blood pressure aOR = 0.31; CI, 95% CI [0.13-0.72], p < 0.008. Prevention policiesshould take into account blood cardiometabolic level for subjects with high blood pressure even though in the steady sate.

Introduction: Due to its frequency and its complications, it constitutes a major public health problem in the world, particularly in Africa. According to the WHO, 350 million people suffer from chronic liver disease in the world, and Africa has 60 million with a quarter of deaths per year. The objective of our study was to describe the epidemiological aspects of cirrhosis at the Sominé DOLO Regional Hospital in Mopti, the first in the region. Methods and Patients: This is a descriptive cross-sectional study extending from January 1, 2021 to December 2021, carried out in the medical department of the Sominé Dolo hospital in Mopti. The diagnosis of cirrhosis was retained in the face of arguments: clinical: oedemato-ascites syndrome, portal hypertension syndrome, hepatocellular insufficiency syndrome; biologicals of hepatocellular insufficiency syndrome; ultrasound suggestive of cirrhosis (hepatic atrophy, hepatomegaly, irregular contours, heterogeneous echostructure, portal trunk greater than 15 mm in diameter, maximum portal blood flow velocity less than 15 cm/s , superior splenic vein 10 mm, splenomegaly and ascites); endoscopic (esophageal varices, cardio-tuberosity varices, antral vascular ectasia, portal hypertension gastropathy. Despite these clinical, biological and imaging arguments, the diagnosis of certainty remains the liver biopsy puncture. Result: The analysis concerned 46 patients out of the 865 hospitalized patients, ie a frequency of 5.31%. The average age was 47.5 with extremes of 21 and 70 years. The most represented age group was 46 – 65 years old. The patients were divided into 34 men (73.9%) and 12 women (26.1%) i.e. a sex ratio of 2.8. Farmers/herders and housewives accounted for 76.1% (35/46) of the patients and the majority were rural (89.1%). The clinical signs found on hospitalization were: abdominal pain (82.6%), impaired general condition syndrome (80.4%), ascites (76.1%), OMI (58.7%), Hepatomegaly (52.2%), CVC (43.8%), jaundice (32.6), ...

Serum AFP as a poor clinical performance values especially when it comes to deal with the early and AFP-negative diagnostic of HCC. The aim of this work was to assess the contribution of AFP in the diagnosis of HCC. : A total of 95 subjects was enrolled a prospective observational study by consecutive enrolment and divided in two groups. The first group was made up with subjects in whom the diagnosis of HCC had been retained while the second was the control group which was free of HCC. AFP levels were performed by electrochemiluminescence immunoassay on the cobas e411. Data were captured in Excel and analyzed by Ri386 version 4.1.2 binary for macOS 10.13. The Log of median of AFP in HCC subjects was significantly greater than in non HCC subjects 6.91 ng/mL versus 1.43 ng/mL, Wilcoxon < 0.001. At the cut-off of 200 ng/mL, the clinical performances showed an acceptable sensitivity 97.1% CI 95% [93.7 – 100] but a poor specificity 73,8% CI 95% [64.9 – 82.6] and out of the 34 cases of HCC, one case (2.9%) was AFP-negative HCC. our data show an acceptable sensitivity but a weak specificity of AFP as a biomarker for HCC at cut-off 200 ng/mL. This suggests that AFP should be used with other biomarkers mainly for the early and AFP-negative HCC diagnosis.